Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genscript Biotech's change in inventory for the quarter that ended in Dec. 2025 was $-2.2 Mil. It means Genscript Biotech's inventory
increased by $2.2 Mil
from Jun. 2025 to Dec. 2025 .
Genscript Biotech's change in inventory for the fiscal year that ended in Dec. 2025 was $-8.6 Mil. It means Genscript Biotech's inventory
increased by $8.6 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Genscript Biotech's Days Inventory for the quarter that ended in Dec. 2025 was 34.36.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Genscript Biotech's Inventory Turnover for the quarter that ended in Dec. 2025 was 5.31.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genscript Biotech's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.09.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genscript Biotech's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech Change In Inventory Related Terms
Genscript Biotech Change In Inventory Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $-8.6 Mil mean?
Genscript Biotech (GNNSF) has a Change In Inventory of $-8.6 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Genscript Biotech and its competitors.
Is Genscript Biotech's Change In Inventory too high?
Genscript Biotech's current Change In Inventory is $-8.6 Mil. Overall, Genscript Biotech has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Change In Inventory compare to VRTX and REGN?
Genscript Biotech's Change In Inventory of $-8.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Genscript Biotech and its competitors. Genscript Biotech's current Change In Inventory is $-8.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Fairly Valued. The stock's GF Value™ is $3.12, compared to a current price of $3.08 — trading 1.3% below its estimated fair value. The current Change In Inventory is $-8.6 Mil. Genscript Biotech's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Change In Inventory is $-8.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $3.08 is trading 1.3% below its estimated GF Value™ of $3.12.
GuruFocus considers Genscript Biotech to be Fairly Valued.
Key valuation signals for GNNSF:
Change In Inventory: $-8.6 Mil
GF Value™: $3.12 vs. price of $3.08 (1.3% below fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
74GF Score
Get the complete analysis for GNNSF
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
